LOS ANGELES CAPITAL MANAGEMENT LLC
Position in MYGN — Myriad Genetics Inc
CIK 1177206
LOS ANGELES, CA
Position in MYGN
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$392,310
-$206,816 QoQ
Shares Held
87,180
-10.5% QoQ
Ownership
0.092%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 41%
Shared 0%
None 59%
Common Shares in MYGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026LOS ANGELES CAPITAL MANAGEMENT LLC holds $165,100,615 across 27 Diagnostics & Research names. MYGN ranks #11 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IDXX |
Idexx Laboratories Inc /De
|
227,369 | $127,756,367 | |
| 2 | MEDP |
Medpace Holdings, Inc.
|
45,686 | $21,937,960 | |
| 3 | IQV |
Iqvia Holdings Inc.
|
33,168 | $5,656,470 | |
| 4 | VCYT |
Veracyte, Inc.
|
91,401 | $2,944,026 | |
| 5 | SHC |
Sotera Health Co
|
120,851 | $1,733,003 | |
| 6 | GH |
Guardant Health, Inc.
|
10,766 | $994,455 | |
| 7 | TMO |
Thermo Fisher Scientific Inc.
|
1,631 | $801,685 | |
| 8 | WGS |
GeneDx Holdings Corp.
|
10,103 | $648,814 |
All Filings in MYGN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $392,310 | 87,180 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $599,126 | 97,419 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $588,493 | 81,396 | Shares | Sole | 2025-10-20 | |
| No filing history on record for this holder in this stock. | ||||||